UPDATE 1-Almirall gets FDA approval for migraine drug

* Says first of its kind cleared for adolescents

* Patent extended to November 2015

* Shares up 1.6 percent

(Adds detail, shares)

MADRID, June 3 (Reuters) - Spanish pharmaceutical firm Almirall (ALM.MC) on Wednesday said its Almotriptan migraine drug had gained U.S. Food and Drug Administration approval for adolescents.

The drug -- marketed with U.S. partner Johnson & Johnson's (JNJ.N) Ortho-McNeil Janssen Pharmaceuticals -- was already sold to treat migraines in adults, but is the first of its kind to be approved by the FDA for adolescents, Almirall said.

"This is a huge step for Almirall and our North American partner as it shows our commitment to giving adolescents with migraines a treatment that has not existed to date," it said.

Almirall's patent on Almotriptan in the United States has been extended to November 2015.

By 0708 GMT, Almirall's shares had gained 1.6 percent to 8.42 euros. (Reporting by Tracy Rucinski; Editing by Hans Peters)